Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Julio Dotor García‐Soto"'
Autor:
Diego Santos‐García, Teresa deDeus Fonticoba, Carlos Cores Bartolomé, María J. Feal Painceiras, Iago García Díaz, María Cristina Íñiguez Alvarado, Jose Manuel Paz, Silvia Jesús, Marina Cosgaya, Juan García Caldentey, Nuria Caballol, Ines Legarda, Jorge Hernández Vara, Iria Cabo, Lydia López Manzanares, Isabel González Aramburu, Maria A. Ávila Rivera, Víctor Gómez Mayordomo, Víctor Nogueira, Julio Dotor García‐Soto, Carmen Borrué, Berta Solano Vila, María Álvarez Sauco, Lydia Vela, Sonia Escalante, Esther Cubo, Zebenzui Mendoza, Juan C. Martínez Castrillo, Pilar Sánchez Alonso, Maria G. Alonso Losada, Nuria López Ariztegui, Itziar Gastón, Jaime Kulisevsky, Manuel Seijo, Caridad Valero, Ruben Alonso Redondo, Maria Teresa Buongiorno, Carlos Ordás, Manuel Menéndez‐González, Darrian McAfee, Pablo Martinez‐Martin, Pablo Mir, COPPADIS Study Group
Publikováno v:
Brain and Behavior, Vol 13, Iss 12, Pp n/a-n/a (2023)
Abstract Background and objective Recently, we demonstrated that staging Parkinson's disease (PD) with a novel simple classification called MNCD, based on four axes (motor, non‐motor, cognition, and dependency) and five stages, correlated with dise
Externí odkaz:
https://doaj.org/article/ff18adaf795b4fa18e371b0bac7f9d77
Autor:
Sara Eichau, Rocío López Ruiz, María Ruíz de Arcos, Juan Luis Ruiz-Peña, Guillermo Navarro, Miguel Ángel Calleja, José Luis Moreno-Amador, Julio Dotor García-Soto
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
BackgroundAlemtuzumab (ALZ) is a humanized monoclonal antibody approved for the treatment of patients with highly active relapsing-remitting multiple sclerosis (RRMS) administered in two annual courses. The objective of this study was to describe the
Externí odkaz:
https://doaj.org/article/094fc9f9f7414c1781855e49921d42f0
Autor:
Diego Santos-García, Teresa de Deus Fonticoba, Carlos Cores Bartolomé, Maria J. Feal Painceiras, Maria Cristina Íñiguez-Alvarado, Silvia Jesús, Maria Teresa Buongiorno, Lluís Planellas, Marina Cosgaya, Juan García Caldentey, Nuria Caballol, Ines Legarda, Jorge Hernández Vara, Iria Cabo, Lydia López Manzanares, Isabel González Aramburu, Maria A. Ávila Rivera, Víctor Gómez Mayordomo, Víctor Nogueira, Víctor Puente, Julio Dotor García-Soto, Carmen Borrué, Berta Solano Vila, María Álvarez Sauco, Lydia Vela, Sonia Escalante, Esther Cubo, Francisco Carrillo Padilla, Juan C. Martínez Castrillo, Pilar Sánchez Alonso, Maria G. Alonso Losada, Nuria López Ariztegui, Itziar Gastón, Jaime Kulisevsky, Marta Blázquez Estrada, Manuel Seijo, Javier Rúiz Martínez, Caridad Valero, Mónica Kurtis, Oriol de Fábregues, Jessica González Ardura, Ruben Alonso Redondo, Carlos Ordás, Luis M. L. López Díaz, Darrian McAfee, Pablo Martinez-Martin, Pablo Mir, Study Group COPPADIS
Publikováno v:
Parkinson's Disease, Vol 2023 (2023)
Introduction. Drooling in Parkinson’s disease (PD) is frequent but often goes underrecognized. Our aim was to examine the prevalence of drooling in a PD cohort and compare it with a control group. Specifically, we identified factors associated with
Externí odkaz:
https://doaj.org/article/81cf020ff63443259403ed892b65e659
Autor:
Diego Santos-García, Teresa de Deus Fonticoba, Carlos Cores Bartolomé, Maria J. Feal Painceiras, Ester Suárez Castro, Héctor Canfield, Cristina Martínez Miró, Silvia Jesús, Miquel Aguilar, Pau Pastor, Lluís Planellas, Marina Cosgaya, Juan García Caldentey, Nuria Caballol, Ines Legarda, Jorge Hernández-Vara, Iria Cabo, Lydia López Manzanares, Isabel González Aramburu, Maria A. Ávila Rivera, Víctor Gómez Mayordomo, Víctor Nogueira, Víctor Puente, Julio Dotor García-Soto, Carmen Borrué, Berta Solano Vila, María Álvarez Sauco, Lydia Vela, Sonia Escalante, Esther Cubo, Francisco Carrillo Padilla, Juan C. Martínez Castrillo, Pilar Sánchez Alonso, Maria G. Alonso Losada, Nuria López Ariztegui, Itziar Gastón, Jaime Kulisevsky, Marta Blázquez Estrada, Manuel Seijo, Javier Rúiz Martínez, Caridad Valero, Mónica Kurtis, Oriol de Fábregues, Jessica González Ardura, Ruben Alonso Redondo, Carlos Ordás, Luis M. López Díaz, Darrian McAfee, Pablo Martinez-Martin, Pablo Mir, COPPADIS Study Group
Publikováno v:
Diagnostics, Vol 12, Iss 5, p 1147 (2022)
Objective: The aim of the present study was to analyze the progression of non-motor symptoms (NMS) burden in Parkinson’s disease (PD) patients regarding the development of motor fluctuations (MF). Methods: PD patients without MF at baseline, who we
Externí odkaz:
https://doaj.org/article/1218cb6a14ba4fd18f2a0c554798e52f
Autor:
Tamara Castillo-Triviño, Rocío Gómez-Ballesteros, Mónica Borges, Jesús Martín-Martínez, Javier Sotoca, Ana Alonso, Ana B. Caminero, Laura Borrega, José L. Sánchez-Menoyo, Francisco J. Barrero-Hernández, Carmen Calles, Luis Brieva, María R. Blasco-Quílez, Julio Dotor García-Soto, María del Campo-Amigo, Laura Navarro-Cantó, Eduardo Agüera, Moisés Garcés-Redondo, Olga Carmona, Laura Gabaldón-Torres, Lucía Forero, Mariona Hervás, Jorge Mauriño, Susana Sainz de la Maza
Publikováno v:
Multiple Sclerosis and Related Disorders
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO. Repositorio Institucional de Producción Científica
instname
Background: Multiple sclerosis is one of the most common causes of neurological disability in young adults with major consequences for their future lives. Improving communication strategies on prognosis may help patients deal with the disease and adj
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77398d9ccef2b31dda2ff6a97b573ecc
https://hdl.handle.net/10668/22397
https://hdl.handle.net/10668/22397
Autor:
Susana Sainz de la Maza, Rocío Gómez-Ballesteros, Mónica Borges, Jesús Martín-Martínez, Javier Sotoca, Ana Alonso, Ana B Caminero, Laura Borrega, José L Sánchez-Menoyo, Francisco J Barrero-Hernández, Carmen Calles, Luis Brieva, María R Blasco-Quílez, Julio Dotor García-Soto, María del Campo-Amigo, Laura Navarro-Cantó, Eduardo Agüera, Moisés Garcés-Redondo, Olga Carmona, Laura Gabaldón-Torres, Lucía Forero, Mariona Hervàs, Nicolás Medrano, Jorge Maurino, Tamara Castillo-Triviño
Publikováno v:
Multiple Sclerosis Journal - Experimental, Translational and Clinical. 9:205521732311694
Disability accrual is mainly driven by progression independent of relapse activity, which is present even in early stages of relapsing-remitting multiple sclerosis (RRMS) and sometimes overlooked. This multicenter, non-interventional study evaluated
Autor:
Marina Cosgaya, Jose M. Paz González, Esther Cubo, Maria G. Alonso Losada, Nuria López Ariztegui, Isabel González Aramburu, Carmen Borrué, Lydia López Manzanares, Jaime Kulisevsky, Iria Cabo, Julio Dotor García-Soto, Pau Pastor, Carlos Cores Bartolomé, Nuria Caballol, Jessica González Ardura, Lucía García Roca, Berta Solano Vila, Luis M. López Díaz L, Víctor Puente, Pablo Martinez-Martin, Juan García Caldentey, Javier Rúiz Martínez, Lydia Vela, Cristina Martínez Miró, Itziar Gastón, Lucía Naya Ríos, Francisco Carrillo Padilla, Ruben Alonso Redondo, Darrian McAfee, Juan C. Martínez Castrillo, Ines Legarda, Silvia Jesús, Carlos Ordás, Víctor Nogueira, Marta Blázquez Estrada, Oriol de Fábregues, Miquel Aguilar, Hector Canfield, Manuel Seijo, Teresa de Deus Fonticoba, Jorge Hernández Vara, Maria A. Ávila Rivera, Pablo Mir, Pilar Sánchez Alonso, Diego Santos García, Lluis Planellas, Caridad Valero, Monica M. Kurtis, Víctor Gómez Mayordomo, Sonia Escalante, María Álvarez Sauco
Publikováno v:
Journal of Parkinsons Disease
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
[Background] Constipation has been linked to cognitive impairment development in Parkinson’s disease (PD). Objective:Our aim was to analyze cognitive changes observed in PD patients and controls from a Spanish cohort with regards to the presence or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e64a9cb2d616315aceae302a1f891268
http://hdl.handle.net/10261/305139
http://hdl.handle.net/10261/305139
Autor:
Laura Gabaldón-Torres, Javier Sotoca, Ana B Caminero, Laura Borrega, Rocío Gómez-Ballesteros, Lucía Forero, Laura Navarro-Cantó, Eduardo Agüera, Tamara Castillo-Triviño, Jorge Maurino, Olga Carmona, Lucía Ruiz de Alda, Moisés Garcés, María del Campo-Amigo, Julio Dotor García-Soto, Jose Luis Sanchez-Menoyo, Carmen Calles, Jesús Martín-Martínez, Maria R Blasco, Mónica Borges, Luis Brieva, Mariona Hervás, Ana Alonso, Francisco J Barrero-Hernández, Susana Sainz de la Maza
Publikováno v:
Multiple Sclerosis and Related Disorders
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO. Repositorio Institucional de Producción Científica
instname
Background: Multiple sclerosis is one of the most common causes of neurological disability in young adults with major consequences for their autonomy and capacity to maintain employment. Objective: The aim of this study was to assess the impact on wo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25c438ee12d41a622e3e8e0747b1d0be
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=13652
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=13652
Autor:
Rocío López Ruiz, María Ruiz de Arcos, Félix Sánchez Fernández, Guillermo Navarro Mascarell, Sara Eichau, Juan Luis Ruiz Peña, Juan Diego Guerra Hiraldo, Julio Dotor García-Soto, Alejandro Fuerte Hortigón, M Dolores Páramo Camino
Publikováno v:
Neurol Clin Pract
Background and Objective:The most common adverse events following Alemtuzumab include adverse infusion reactions, infections and autoimmune disorders. Skin adverse events are common during infusion but there are few reported cases of long-term skin a
Autor:
María Dolores Páramo Camino, Guillermo Navarro Mascarell, Juan Luis Ruiz-Peña, Rocío López Ruiz, Julio Dotor García-Soto, Sara Eichau, Félix Sánchez Fernández
Publikováno v:
Neurología Argentina. 12:66-68
Resumen Introduccion Teriflunomida es un agente inmunomodulador aprobado para el tratamiento de la esclerosis multiple remitente-recurrente, que actua como inhibidor de la enzima dihidroorotato-deshidrogenasa, impidiendo la proliferacion linfocitaria